Liminatus Pharma (NASDAQ:LIMN) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Liminatus Pharma (NASDAQ:LIMN) from a hold rating to a strong sell rating in a report published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Liminatus Pharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Liminatus Pharma presently has a consensus rating of “Sell”.

Liminatus Pharma Stock Performance

Shares of LIMN stock opened at $0.72 on Friday. The company’s 50-day moving average is $1.36. Liminatus Pharma has a 1-year low of $0.61 and a 1-year high of $33.66. The company has a market capitalization of $19.46 million and a P/E ratio of -5.99.

Liminatus Pharma (NASDAQ:LIMN) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.